<?xml version="1.0" encoding="UTF-8"?>
<p>Co-infection with 
 <italic>Mycobacterium tuberculosis</italic> (Mtb) and the human immunodeficiency virus (HIV-1), the agents of tuberculosis (TB) and acquired immunodeficiency syndrome (AIDS), respectively, is a major health issue. Indeed, TB is the most common illness in HIV-1-infected individuals, about 55% of TB notified patients are also infected with HIV-1, and about a fifth of the TB death toll occurs in HIV-1 co-infected individuals (WHO health report 2017). Clinical studies evidence a synergy between these two pathogens, which is associated with a spectrum of aberration in immune function (
 <xref rid="bib12" ref-type="bibr">Esmail et al., 2018</xref>). Yet, while progress has been made towards understanding how HIV-1 enhances Mtb growth and spread, the mechanisms by which Mtb exacerbates HIV-1 infection require further investigation (
 <xref rid="bib3" ref-type="bibr">Bell and Noursadeghi, 2018</xref>; 
 <xref rid="bib9" ref-type="bibr">Deffur et al., 2013</xref>; 
 <xref rid="bib10" ref-type="bibr">Diedrich and Flynn, 2011</xref>).
</p>
